Fresenius Acquires Full Ownership of mAbxience for €750 Million

Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience Holding S.L. for up to €750 million. This strategic move grants Fresenius full control, enhancing its competitive position in the expanding biosimilars market. The acquisition aligns with Fresenius' #FutureFresenius strategy, promising immediate positive impacts on its earnings per share.

mAbxience, a global player in the biopharmaceuticals sector, operates advanced facilities in Spain and Latin America. With full ownership, Fresenius aims to optimize its investment and manufacturing capacities as the biosimilars market is predicted to grow to over €180 billion by 2035. This acquisition marks a significant step in establishing a vertically integrated biopharma business, covering research to commercialization.

Financially, the acquisition doesn't necessitate new financing, and is expected to bolster Fresenius' return on invested capital. Michael Sen, CEO of Fresenius, emphasized the strategic advantage gained through complete control and economic benefits. The transaction, consistent with Fresenius' capital priorities, also supports future innovation and increased patient access to high-quality biosimilars.